Neoplasms

All Conditions

Carcinoma

Carcinoma, Squamous Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

defned as having no more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy

defned as having more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy

The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.

Pathological response assessment

Hongtao Duan, Dr.

To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy

The biobank of thoracic surgery department of Tangdu Hospital collected pre-treatment tissues from patients during endoscopy. The investigators retrospectively summarized the clinical characteristics of these patients and patients with operable locally advanced lung squamous cell carcinoma were selected and followed.

The investigators plan to employ snRNA-seq and scRNA-seq respectively to profile 20 samples of paired pre-treatment and post-treatment tumors from ten patients (discovery cohort) to create a cell atlas for analysis, and spatial transcriptomics to examine 8 samples from four patients. In discovery cohort, estimated 5 patients achieve major pathological response (MPR) and 5 patients achieve non-MPR after NICB.

After analyzing the results of discovery cohort, the investigators will collect frozen tissues and formalin-fixed, paraffin-embedded (FFPE) tissue from our biobank for bulk RNA-seq analysis or immunohistochemistry (IHC) staining as validation cohort to further investigate the predictive value and biological significance of our markers.

pre-treatment and post-treatment tumors from patients with operable locally advanced lung squamous cell carcinoma

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma

MPR: Resected tumors with ≤10% viable tumor cells were considered to have a MPR

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma	NCT06436040	Tumor Microenvi... Lung Squamous C... Neoadjuvant Che...	Pathological re...	40 Years - 80 Years	Tang-Du Hospital

Spots Global Cancer Trial Database for pathological response assessment